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Lichen sclerosus (LS) is considered to have an immunogenetic background. Several small studies, using sero-
logical typing, have reported that HLA-DR11, DR12, and DQ7 were increased in LS, with DR17 less frequent. This
study aimed to validate and detect new HLA-DR and DQ associations with LS in females and its characteristic
clinical parameters. The cases, 187 female LS patients, and 354 healthy controls were all UK North Europeans. PCR-
sequence specific primers method was applied to genotype the HLA-DR, DQ polymorphisms that correspond to 17
serologically deﬁned DR and seven DQ antigens. Statistical analysis was performed with two-tailed Fisher’s exact
test with Bonferroni adjustment (p value after Bonferrroni adjustment, Pc). We found increased frequency of
DRB112 (DR12) (11.2% vs 2.5%, pco0.01) and the haplotype DRB112/DQB10301/04/09/010 (11.2% vs 2.5%,
po0.001, pco0.05), and a lower frequency of DRB10301/04 (DR17) (11.8% vs 25.8%, pco0.01) and the haplotype
DRB103/DQB102DRB10301/DQB10201/02/03 (11.2% vs 24.6%, pco0.0001) in patients compared with controls.
HLA DR and DQ antigens were not associated with time of onset of disease, site of involvement, structural changes
of genitals, and response to treatment with potent topical steroids. In conclusion, HLA-DR and DQ antigens or their
haplotypes appear to be involved in both susceptibility to and protection from LS.
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Lichen sclerosus (LS) is a chronic inflammatory disease that
has a predilection for the anogenital area. It is characterized
clinically by plaques of ivory white atrophic or thickened
skin. In the majority of patients, there is progressive disease
with genital structural changes or scarring (Ridley, 1988).
Although it is common in postmenopausal women, there are
increasing numbers of reports of girls with LS (Powell and
Wojnarowska, 2001). The current management of LS is
topical potent steroids that relieve the symptoms and
sometimes reverse the clinical signs (Dalziel et al, 1991;
Sinha et al, 1999; Cooper et al, 2004).
There has been accumulating evidence that immunolog-
ical reactions are involved in the onset and pathogenesis of
LS (Farrell et al, 1999; Carlson et al, 2000; Lukowsky et al,
2000). The association of autoimmune diseases with LS has
been well documented in clinical studies (Meyrick Thomas
et al, 1988; Marren et al, 1995; Lewis, 1998; Powell et al,
2000). The recent demonstration that skin autoantibodies,
targeting extracellular matrix protein 1 and basement mem-
brane zone antigens, are present in LS which further sup-
ports an immunological basis for LS (Oyama et al, 2003;
Howard et al, 2004). A genetic basis for disease suscep-
tibility is suggested by case reports of familial aggregation
of LS and other autoimmune disease, which has been re-
ported in up to 17% of female children with LS (Sahn et al,
1994; Powell and Wojnarowska, 2001). Two studies showed
that HLA DQ3 and specifically DQ7 were more frequent in
females with LS than controls (Marren et al, 1995; Powell
et al, 2000), especially in girls with LS (Powell et al, 2000),
suggesting a role in susceptibility to LS. DR 17 was less
frequent in girls with LS than the controls (Powell et al,
2000). Further analysis suggested that the DR4/DQ8 ha-
plotype was less frequent in vulval LS with structural
changes than those without, suggesting a role in disease
progression (Marren et al, 1995). Another study of LS in
adult men showed increased frequencies of DR11, DR12,
and DQ7 (Azurdia et al, 1999).
Abbreviations: LS, lichen sclerosus; Pc, p value after Bonferrroni
adjustment
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In this study, we have collected and genotyped the larg-
est cohort of ethnically homogeneous North European fe-
male LS patients with the aim of replicating the associations
between polymorphic HLA DR, DQ antigens, and LS. Pos-
sible novel associations between DR, DQ polymorphisms,
and clinical parameters of LS were also investigated.
Results
Clinical data Clinical information was available from 187
LS patients, but was incomplete in a minority. The results
are summarized in Table I.
HLA-DR and HLA-DQ frequencies in LS and controls
Single loci The allele frequencies of the 187 female LS and
354 controls are shown in Table II. There were more patients
than controls with DRB112 genotypes (11.2% vs 2.5%,
pco0.005). There were fewer patients than controls with
DRB10301/04 (11.8% vs 25.8%, pco0.005). These data
suggest that the former might be a susceptibility gene, and
the latter a protective gene for LS. There were no other
significant differences in frequency of alleles between the
patients and controls.
Haplotypes Among 57 estimated haplotypes, only haplo-
types DRB112/DQB10301/04/09/010 (11.2% vs 2.5%,
pco0.05, RR¼ 4.84) and DRB10301/04/DQB10201/02/
03 (11.2% vs 24.6%, pco0.0001, RR¼0.39) reached sta-
tistical differences between patients and controls after
Bonferroni correction. Haplotype DRB115/DQB106 was
less frequent in LS than controls (17.1% vs 28.6%, po0.01,
RR¼0.52), and DRB113/DQB106 was more frequent in
LS than controls (24.6% vs 16.4%, po0.05, RR¼1.66);
their statistical differences were lost after Bonferroni cor-
rection. Other 53 haplotype frequencies were similar be-
tween patients and controls (p40.05).
DR and DQ polymorphism in association with clinical
parameters Different DR, DQ phenotypes or haplotypes
might influence clinical parameters in females with LS. We
therefore analyzed whether there were any associations
between DR, DQ phenotypes and haplotypes, and certain
clinical parameters using Fisher’s exact test.
Age and timing of onset The patients were grouped into
onset in childhood (pre-menarche) and post-menarche. As
shown in Table I, data on the age and timing of onset in
relation to menarche were obtained from 168 patients. There
were significantly increased frequencies of DRB112 as
compared with the controls in both LS girls with onset pre-
menarche (17.1% vs 2.5%, po0.001, pco0.05, RR¼7.91)
and women with LS onset post-menarche (9.8% vs 2.5%,
po0.01, pco0.05, RR¼4.141). There was a significantly
decreased frequency of DRB10301/04 in LS of post-men-
arche onset, as compared with the controls (9.0% vs 25.8%,
po0.0001, pco0.001, RR¼0.286). But there were no sig-
nificant differences of DR or DQ allele frequencies between
patients with onset in childhood or later in life.
Site of involvement The patients were grouped into those
with anogenital involvement alone and those with anogenital
involvement and extragenital involvement. There were no
DR, DQ phenotype associations with site of involvement.
Structural changes or scarring The patients were grouped
into those patients without structural changes and those
with structural changes. The DRB104/DRB108 haplotype
was present in 34 (26.3%) patients with structural changes,
and seven (14.5%) patients without structural changes,
(p40.05). We were not able to confirm our finding in a pre-
vious smaller study that this haplotype was less common in
LS patients with structural changes compared with those
without (Marren et al, 1995).
Steroid treatment response As the clinical signs objectively
reflect the treatment response by steroid, we analyzed the
influence of DR, DQ polymorphisms on those patients with
good improvement, partial improvement, and poor re-
sponse to topical steroid. Different DR, DQ phenotypes
had no association with improvement of clinical signs by
topical steroids.
Patients with other autoimmune disorders The patients were
grouped into those with and without systemic or organ-
specific autoimmune disease. There were fewer DRB113
positive LS patients (10 of 60, 16.7%) with other autoim-
mune diseases than those without other autoimmune dis-
eases (36 of 119, 30.3%), (po0.05) indicating DR13 might
have a protective role against autoimmunity in female LS
patients.










Age of onset o0.5–86 y
(mean value 44.6 y)
187





Sites Anogenital 187 (100) 187
Extragenital 20 (11)
Structural Severe 52 (31) 166
Change Moderate 66 (40)
None 48 (29)
Treatment Resolution 25 (16) 152
Response Partial 109 (72)
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Discussion
We report positive associations in vulval LS with DRB112
(11.2% vs 2.5%, pco0.005) and the haplotype DRB112/
DQB10301/04/09/010 (11.2% vs 2.5%, pco0.05). In ad-
dition, negative associations are reported with DRB10301/
04 (11.8% vs 25.8%, po0.05) and the haplotype
DRB10301/04/DQB10201/02/03 (11.2% vs 24.6%,
pco0.0001).
There are several possible risks and errors in carrying out
and interpreting an association study, for example, small
sample size, multiple testing, poorly matched control group,
failure to detect linkage disequilibrium with adjacent loci
(Cardon and Bell, 2000; Gambaro et al, 2000). Although we
collected the largest ever female LS cohort for HLA class II
association study, more samples are needed to ensure an
analysis with sufficient power. We ensured that patients and
controls were exclusively North European white Caucasians
to ensure a homogenous population.
In this study, we found that DQB1301/04/09/010 was
carried by 42.8% of the whole LS cohort and by 50.0% of
patients with disease of pre-menarche onset. Previous
studies showed that DQ7 (DQB1301/04/09/010) was
present in 50% of female LS and 66% of girls with LS
(Marren et al, 1995; Powell et al, 2000). There were more
DQB1301/04/09/10 positive subjects in our control cohort
(41.6%) than the controls of previous study, which were
renal transplant donors and not ethnically matched (25%)
(Marren et al, 1995; Powell et al, 2000). This explains why
we could not demonstrate an increased prevalence of
DQB130104/09/010 in our vulval LS patients.
Interestingly, we found that the DRB112/DQB103 ha-
plotype was more prevalent in vulval LS patients than in
controls (pco0.05). These data suggest that there may be
several susceptibility genes for LS. In contrast, the lowered
frequency of the DRB10301/04/DQB10201/02/03 (pco
0.0001) haplotype may indicate a protective role in the
pathogenesis of LS. A further study with high-resolution
genotyping is required to pinpoint the exact allelic haplo-
type of these haplotypes.
Elderly women have LS more often than younger women,
and there are increasing numbers of young females and pre-
Table II. Frequencies of individual or grouped alleles in LS and controls
Alleles Phenotypes
Number of subjects with allele frequencies (%)
p-value pc-value RRLS (187) number (%) Controls (354) number (%)
DRB10101/02/04–07 DR1 26 (13.9) 67 (19.0) 0.151 NS 0.689
DRB10103 DR103 2 (1.1) 13 (3.7) 0.10 NS 0.283
DRB104 DR4 80 (42.8) 131 (37.1) 0.228 NS 1.267
DRB10701/03/04 DR7 71 (38.0) 91 (25.8) 0.004 NS 1.762
DRB108 DR8 9 (4.8) 13 (3.7) 0.503 NS 1.322
DRB10901 DR9 5 (2.7) 10 (2.8) 1 NS 0.942
DRB11001 DR10 0 0 NS
DRB111 DR11 25 (13.4) 59 (16.7) 0.322 NS 0.769
DRB112 DR12 21 (11.2) 9 (2.5) 0.00009 0.002 4.835
DRB113 DR13 48 (25.7) 70 (19.8) 0.191 NS 1.396
DRB114 DR14 9 (4.8) 21 (5.9) 0.691 NS 0.799
DRB115 DR15 32 (17.1) 101 (28.6) 0.00324 NS 0.515
DRB116 DR16 4 (2.1) 3 (0.8) 0.242 NS 2.550
DRB10301/04 DR17 22 (11.8) 91 (25.8) 0.000096 0.002 0.384
DRB501/02 DRw51 36 (19.3) 103 (29.2) 0.013 NS 0.579
DRB301/02/03 DRw52 107 (57.2) 214 (60.6) 0.462 NS 0.869
DRB401 DRw53 126 (67.4) 222 (62.9) 0.345 NS 1.219
DQB102 01/02/03 DQ2 72 (38.5) 144 (40.8) 0.645 NS 0.909
DQB10401/02 DQ4 7 (3.7) 13 (3.7) 1 NS 1.017
DQB10501/02–4 DQ5 43 (23.0) 96 (27.2) 1 NS 0.799
DQB106 DQ6 74 (39.6) 148 (42.0) 0.646 NS 0.907
DQB10301/04/09/010 DQ7 80 (42.8) 147 (41.6) 0.855 NS 1.048
DQB10302/07/08 DQ8 43 (23.0) 59 (16.7) 0.083 NS 1.488
DQB10303/06 DQ9 21 (11.2) 33 (9.3) 0.547 NS 1.227
pc-value, after Bonferroni adjustment (factor¼ 24); NS, not significant; LS, lichen sclerosus.
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menarche girls affected by LS, when levels of sex hormones
are low (Ridley, 1988; Powell and Wojnarowska, 1999, 2001;
Powell et al, 2000). in this cohort 75.9% had disease onset
either pre-menarche or postmenopausal. Polymorphisms of
HLA may influence the level of sex hormones (Ollier et al,
1989; Larsen et al, 2000). We could not find any DR, DQ
haplotypes that influenced the stage of reproductive life at
which onset of LS occurred. LS patients with different ages
of onset might have exposure to different antigenic stimuli,
such as virus, bacteria, or even self-antigen peptides. These
antigenic factors might require different polymorphisms of
HLA class II molecules to elicit or block an immune response
(Phelps et al, 1996; Burg et al, 2001).
The extent of lesional involvement and structural chang-
es are two important parameters with which to assess se-
verity of LS. A previous study reported that DR4/DQ8 was
less common in patients with structural changes (Marren
et al, 1995). We could not confirm this association in this
study, because of the small numbers with this haplotype,
nor could we find any other DR, DQ polymorphism in as-
sociations with these two parameters. It seems that severity
of LS is not related to HLA DR and DQ antigens.
Topical steroids are the most widely used option for the
management of LS, although the response rate varies (Da-
lziel et al, 1991; Sinha et al, 1999; Cooper et al, 2004). Dif-
ferent DR or DQ antigens may influence steroids sensitivity
in several conditions (Gaag et al, 1990; Bakr and El-
Chenawy, 1998). We could not find any association of DR or
DQ with LS with regard to response of clinical signs to
treatment.
A proportion of LS patients had one or more other au-
toimmune diseases. We found that DRB113 was more
prevalent in those LS patient without autoimmune diseases
than those with autoimmune diseases. Thus DRB113 may
have a protective role against development of other auto-
immune disease in association with LS.
In summary, we found increased frequencies of
DRB112 and the haplotype DRB112/DQB10301/04/09/
010, in vulval LS patients compared with controls, and a
decreased frequency of DRB10301/04 and the haplotype
DRB10301/04/DQB10201/02/03. The results suggested
that the former have a role in susceptibility to, whereas the
latter in protection from the onset of LS. HLA DR and DQ
antigens do not seem to influence the age of onset, disease
severity, or treatment response of LS.
Materials and Methods
Patients and samples One hundred and eighty-seven female LS
patients attending the vulvar clinics of Dermatology Department,
Oxford were enrolled in this study. They were all North European
(country of origin of four grandparents) white UK Caucasians from
Southern England (Oxford region). The criteria for the diagnosis
were: (1) characteristic clinical appearance, (2) histological confir-
mation for adult patients. Patients gave 5–10 mL peripheral blood
for DNA extraction, with informed consent (OxREC 97.149). Con-
trol blood for DNA was taken from 354 UK North European indi-
viduals. The control group was randomly selected from over
10,000 anonymized blood samples collected from nearby health
screening clinics (OXCHECK) between 1987 and 1990. All controls
were from a similar ethnic (white North European) background. One
hundred and eighty of 354 (50.8%) of control individuals were fe-
male, average age was 48.6 y (range 35.1–65.0 y).
Relevant clinical parameters were obtained from LS patients
(Table I), either by direct questionnaire and clinical examination or by
reviewing clinical notes. The recorded parameters include age of on-
set, time of onset in relation to age of menarche and menopause, site
of lesions, signs and their response to treatment with topical steroids,
vulvar structural changes, or scarring. The sites of LS involvement
were classified as anogenital and extragenital. Clinical signs were
mainly pallor, atrophy, hyperkeratosis, and fissuring or ulceration of
the anogenital skin. Severe vulvar structural changes or scarring,
manifest as labial adhesion, resorption, burying of the clitoris, and
narrowing of the introitus, was recorded. Routine management was
application of very potent (or potent) topical steroid twice a day for up
to 12 wk, then when necessary. Treatment response with regard to
objective physical signs was graded as good (complete resolution of
signs except scarring or structural changes), partial (partial and/or
complete resolution of some signs), minor or poor (minor resolution of
signs), no change, or worse. A personal history of systemic and or-
gan-specific autoimmune diseases, including autoimmune thyroid
disease, pernicious anaemia, insulin-dependent diabetes mellitus,
billiary cirrhosis, rheumatoid arthritis, morphea, lichen planus, alo-
pecia, and vitiligo, was also recorded. Central Oxford Research Eth-
ics Committee approval was given for the study. The study was
carried out according to Declaration of Helsinki Principles.
Genotyping A well-established polymerase chain reaction se-
quence-specific primers method (PCR-SSP) was applied for geno-
typing of LS patients (Bunce et al, 1995). Forty-eight pairs of
primers were designed to amplify DRB1, DRB3, DRB4, DRB5, and
DQB1 loci that correspond to 17 DR and seven DQ phenotypes
(Table II). Genotyping for the control cohort was performed using
the same technique, with a difference in primers to allow higher
resolution typing, however, the results of patients and controls
were made comparable by leveling the resolutions of both groups.
Statistics This was performed using SPSS for Windows (A Pearson
Education Company, Massachusetts). Student’s t test and two-
tailed Fisher’s exact test was applied. Bonferonni adjustment was
also applied where necessary, and the result shown as Pcorrected
(Pc). The correction factor for analysis of frequencies of individual or
grouped alleles in LS and controls was 24, and that for analysis of
haplotype frequencies was 57, cutting-off those large numbers of
rare haplotypes with similar small frequencies. The haplotypes were
constructed using the OxDelta programme. The oxdelta program
uses the standard formulae for calculating haplotype frequency,
taking into account linkage disequilibrium (delta).
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